TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cumulative response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: clinical surgical site infection rate
Endpoint domain: Mortality/survival
Primary endpoint: duration of seroma formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of seroma fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements on a trained word list
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: generalization to a non‐trained, prose memory task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corticosteroid requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCA morphine consumption over 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCA morphine consumption over 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of the Pittsburgh rule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of the Pittsburgh rule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first charcoal stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IL‐1α upregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: b* value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of facial pressure ulcers (FPUs)
Endpoint domain: Adverse events/effects
Primary endpoint: Success with voiding trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quality of recovery (QoR-40 emotional state)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pain relief over 12 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of minor pin-track infections
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of loose pins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Prevalence of clinically relevant pin-site complications
Endpoint domain: Adverse events/effects
Primary endpoint: antiviral efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: resistance
Endpoint domain: Adverse events/effects
Primary endpoint: change in visual analog scale pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand hygiene frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in clearing pathogens (GNB and S. aureus)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relative change in MEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relative change in MVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: CSHQ 33‐Item total score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: total hours of sleep per day
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: total minutes awake after sleep onset
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Decreased level of IL‐1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mucosal levels of 5‐HIAA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactulose/L‐rhamnose ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: expression of tight junction proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: migraines/30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability coefficients of walking tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of malignant sequelae
Endpoint domain: Mortality/survival
Primary endpoint: Patients alive in first complete remission at 4 years
Endpoint domain: Mortality/survival
Primary endpoint: 3-year estimated survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Tumour immune microenvironment assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of CD3+/CD8+ tumour-infiltrating lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response to PD-1 inhibitor treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum LDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Repleted iron stores before delivery (ferritin>50 microg/l)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety and effectiveness of CT-guided core needle biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Levels of serum IL‐4 and IL‐10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of serum IL‐2 and gamma‐IFN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sleep disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep-related impairments
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Th17/Treg imbalance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of developing severe ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: total image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time free of illness
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of success at achieving 1psi pressure threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in relevant knowledge (PiRAQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Decrease in scores on the decisional conflict (DCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Return-to-work rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Median time from initial sick leave to partial return-to-work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of SIRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of any organ failure (AOF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of multiple organ failure (MOF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in log peak walking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in PaRTS‐A total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of obsession-induced anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRQ improvement after treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: treatment failures in biomarker-negative exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Disease Activity Score (DAS) 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravenous opioid supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Aldrete score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of anaesthetic procedure satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative reulceration incidence
Endpoint domain: Mortality/survival
Primary endpoint: Progression to AIDS/death avoided
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HIV-related illness avoided
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Global Petty score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in LV mass index (LVMi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in LV diastolic function (E/e' ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Consequential LBP requiring medical attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: arginase activity of tissue samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean adjusted A1C changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: diarrhoea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk that expectations of patients were not met
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients satisfied with their TKA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: F2‐isoprostanes concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein carbonyls concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced mortality from preventable physical illness
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of reflux symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Disturbance of sleep due to reflux
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Days with no new ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe or life-threatening toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Residual Limb Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steps to complete an obstacle course
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant SBP ≥90 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood loss per transection area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Base excess and HCO3- levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hippocampus volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: need for subsequent antibiotic prescription
Endpoint domain: Adverse events/effects
Primary endpoint: skills acquisition on simulators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of metoprolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Health service provider visit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of days abstinent from alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol-related negative consequences
Endpoint domain: Adverse events/effects
Primary endpoint: infiltration by inflammatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: radiological scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary levels of collagen crosslinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of plaque indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful occlusion of aneurysms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: procedure-related permanent morbidity rate
Endpoint domain: Adverse events/effects
Primary endpoint: procedure-related mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of relapse/impending relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete relief of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: episodes requiring rescue antacids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative pain at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain assessed on a visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak serum canthaxanthin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour area under the serum canthaxanthin concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 72-hour area under the serum canthaxanthin concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in LS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort during treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of eyes with all negative cultures after PI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma nitrate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean implant aesthetic score (IAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐144 min) of warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐infinity) of warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaching the target uric acid level of <=6 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transition of bleeding pockets to non bleeding sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean additional reduction in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: cortical thickness in the anterior cingulate cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cerebral fractional oxygen extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: clinically acceptable intubating conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decision conflict
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: likelihood of talking with physician
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of 100% adherent patients to PEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of HIV testing follow-up at D45
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of HIV testing follow-up at M3
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Utilization of spironolactone
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: incidence of adverse clinical events leading to failure of extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utility of secondary stress testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Utility of angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients achieving HIV-1 RNA < 50 copies/ml at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving HIV-1 RNA < 50 copies/ml at week 144
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of MODS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Overall image quality mean scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of VMA at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Categoric ≥ 2‐line and ≥ 3‐line improvement in BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAD anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HRQOL (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: eye symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SⅠT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of cognitive deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Table of Index (TOI) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: FAACT score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CRC incidence or mortality reduction
Endpoint domain: Mortality/survival
Primary endpoint: visual analogue pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental cost per quality-adjusted life-year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity to erythematous effects of UVB irradiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Colonization by MSI1-positive osteoblast precursors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Microvascularization (CD34-positive vascular structures)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Likelihood of having an anxiety disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to reach physiotherapy objective
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients with microembolic signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: median number of microembolic signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Tolerance to PR in patients reactive to CM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absence of IgE to BLG as a marker of PR tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nitric oxide production (NOx/Cr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone resorption markers (PYD/Cr, DPD/Cr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma endotoxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar bone mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone mineral density of the proximal femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net incremental treatment cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: playground peer engagement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: social network salience
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: overall social success
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Spontaneous Bowel Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: ≥90% clearance or moderate improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phonemic verbal fluency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: New occurrences of bacteria in MEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma riboflavin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte FMN concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residue/recurrence of herniation requiring reoperation
Endpoint domain: Adverse events/effects
Primary endpoint: Proliferation of CD8 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes